- After almost seven years in the position
- Praise and thanks for Mattessich
- Pravin Dugel taking over
- Mattessich said 116 words
(exechange) — Bedford, Massachusetts, April 15, 2024 — Antony Mattessich, chief executive of Ocular Therapeutix, leaves his position. As announced by Ocular Therapeutix Inc. in a news release on Monday, April 15, 2024, Antony Mattessich leaves his post as chief executive officer at the biopharmaceutical company, after almost seven years in the role, effective immediately.
Generally speaking, it raises questions when a CEO leaves his post abruptly.
Antony Mattessich’s duties as CEO will be taken over by Pravin U. Dugel, previously Executive Chairman at Ocular Therapeutix Inc.
“Next stage”
Ocular Therapeutix did not give an explicit reason for Antony Mattessich’s departure from the CEO post. Mattessich stated: “Now, with AXPAXLI enrolling in the Phase 3 program with a Special Protocol Assessment, the Company is set to advance to the next stage.”
Precise information regarding Antony Mattessich’s future plans was not immediately available.
“Stepping down”
Ocular Therapeutix said: “Executive Chairman, Pravin U. Dugel, MD, is assuming the roles of President and Chief Executive Officer …, and … Antony Mattessich is stepping down as President and CEO, effective immediately. In addition to his new responsibilities, Dr. Dugel will continue to serve as a director and as Executive Chairman of Ocular.”
Share price decline since April 2021
The announcement follows a decline in Ocular Therapeutix Inc.’s share price of 54% since April 2021.
In the position of CEO since 2017
Antony Mattessich became CEO of the Company in 2017.
Antony Mattessich has served as the Company’s President and Chief Executive Officer since July 2017 and as a member of the Company’s board of directors since June 2017.
Mattessich previously served as Managing Director of Mundipharma International, a therapeutics company, from May 2011 until July 2017.
Prior to serving as Managing Director, Mattessich served in variety of other roles at Mundipharma, including as Head of Western Europe from January 2009 to May 2011 and Managing Director of Napp Pharmaceutical Group, a pharmaceutical company and an independent associated company of Mundipharma, from 2005 until January 2009.
Prior to joining Mundipharma International, he served as Therapeutic Franchise Head of Novartis AG, a pharmaceutical company.
Since September 2021, Mattessich has served as a member of the board of directors of Aura Biosciences, Inc., a biotechnology company.
Mattessich holds a B.A. in Special Studies from the University of California at Berkeley and an M.I.A. from Columbia University.
116 words by Antony Mattessich
In the release announcing his departure as CEO of Ocular Therapeutix Inc., Antony Mattessich received praise and thanks.
In announcing his departure, Antony Mattessich said 116 words.
“I ‘pass the baton’ to Pravin with enthusiasm”
Antony Mattessich stated: “The journey with Ocular Therapeutix over the last seven-plus years has been the highlight of my career. Working with the team to emerge from the aftermath of the second CRL with DEXTENZA™, through approval and launch, has been amazing. Now, with AXPAXLI enrolling in the Phase 3 program with a Special Protocol Assessment, the Company is set to advance to the next stage. As Ocular moves forward to transform into a leading retina care company, I am grateful to the employees, advisors, investors and collaborators who have supported the Company’s development and progress. I ‘pass the baton’ to Pravin with enthusiasm and optimism for all that lies ahead. The Company could not be in better hands.”
The above text is an excerpt from the exechange report 17.2024 ($), publication date April 22, 2024.